OptiNose (OPTN) to Release Quarterly Earnings on Tuesday

OptiNose (NASDAQ:OPTN - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect OptiNose to post earnings of ($0.74) per share and revenue of $17.70 million for the quarter.

OptiNose (NASDAQ:OPTN - Get Free Report) last issued its earnings results on Wednesday, March 26th. The company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.70) by $0.67. The business had revenue of $21.47 million for the quarter, compared to analyst estimates of $21.02 million. On average, analysts expect OptiNose to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

OptiNose Stock Performance

Shares of NASDAQ:OPTN opened at $9.41 on Tuesday. The company has a 50 day moving average price of $8.09 and a 200 day moving average price of $7.54. The stock has a market capitalization of $95.34 million, a price-to-earnings ratio of -2.20 and a beta of -0.88. OptiNose has a 1-year low of $4.82 and a 1-year high of $20.03.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on OPTN shares. HC Wainwright reaffirmed a "neutral" rating and issued a $9.00 target price (down from $18.00) on shares of OptiNose in a research note on Friday, March 21st. Lake Street Capital downgraded OptiNose from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $17.00 to $9.00 in a research note on Thursday, March 20th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $9.00 target price (down previously from $15.00) on shares of OptiNose in a research note on Friday, March 21st.

Insider Buying and Selling

In related news, CEO Ramy A. Mahmoud sold 6,376 shares of the company's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total value of $33,729.04. Following the sale, the chief executive officer now directly owns 126,931 shares of the company's stock, valued at $671,464.99. This represents a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 8,213 shares of company stock valued at $43,643 over the last ninety days. 2.30% of the stock is owned by insiders.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.